Literature DB >> 2653313

Expression of human placental ribonuclease inhibitor in Escherichia coli.

F S Lee1, B L Vallee.   

Abstract

Human placental ribonuclease inhibitor (PRI) has been expressed in and isolated from Escherichia coli. Its apparent molecular weight, immunoreactivity and amino acid composition are virtually identical with those of native PRI. It inhibits the enzymatic activities of either angiogenin, a blood vessel inducing protein homologous to pancreatic RNase (RNase A), or RNase A in a stoichiometry of 1:1. Recombinant PRI binds to angiogenin and RNase A with Ki values of 2.9 x 10(-16) M and 6.8 x 10(-14) M, respectively, comparable to the affinities of native PRI for these enzymes. Thus, these results confirm that PRI inhibits angiogenin more effectively than RNase A.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2653313     DOI： 10.1016/0006-291x(89)91628-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN： 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  Ribonuclease inhibitor: structure and function.

Authors:  Kimberly A Dickson; Marcia C Haigis; Ronald T Raines
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2005

2.  Homogeneity of yellow fever virus strains isolated during an epidemic and a post-epidemic period in West Africa.

Authors:  M R Pisano; J Nicoli; H Tolou
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

3.  Modular mutagenesis of human placental ribonuclease inhibitor, a protein with leucine-rich repeats.

Authors:  F S Lee; B L Vallee
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

4.  Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A.

Authors:  C Z Chen; R Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

5.  Selective abolition of pancreatic RNase binding to its inhibitor protein.

Authors:  Kapil Kumar; Michael Brady; Robert Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-17       Impact factor: 11.205

6.  Ribonuclease A variants with potent cytotoxic activity.

Authors:  P A Leland; L W Schultz; B M Kim; R T Raines
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

7.  Functional expression of recombinant human ribonuclease/angiogenin inhibitor in stably transformed Drosophila melanogaster S2 cells.

Authors:  Jong-Hwa Park; In-Sook Hwang; Kyung-Il Kim; Jong-Min Lee; Young-Min Park; Chang-Ho Park; In Sik Chung
Journal:  Cytotechnology       Date:  2008-01-25       Impact factor: 2.058

8.  Reducing conditions are the key for efficient production of active ribonuclease inhibitor in Escherichia coli.

Authors:  Juozas Siurkus; Peter Neubauer
Journal:  Microb Cell Fact       Date:  2011-05-10       Impact factor: 5.328

9.  Heterologous production of active ribonuclease inhibitor in Escherichia coli by redox state control and chaperonin coexpression.

Authors:  Juozas Šiurkus; Peter Neubauer
Journal:  Microb Cell Fact       Date:  2011-08-08       Impact factor: 5.328

10.  Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity.

Authors:  M J E Havenga; L Holterman; I Melis; S Smits; J Kaspers; E Heemskerk; R van der Vlugt; M Koldijk; G J Schouten; G Hateboer; K Brouwer; R Vogels; J Goudsmit
Journal:  Biotechnol Bioeng       Date:  2008-06-01       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.